SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001600620-24-000041
Filing Date
2024-04-29
Accepted
2024-04-29 16:14:13
Documents
18
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A auph-20231231.htm   iXBRL 10-K/A 863086
2 EX-31.2 exhibit312certificationofp.htm EX-31.2 4105
3 EX-31.3 exhibit313certificationofp.htm EX-31.3 4004
7 auph-20231231_g1.jpg GRAPHIC 83530
8 auph-20231231_g2.jpg GRAPHIC 15830
9 auph-20231231_g3.jpg GRAPHIC 13320
  Complete submission text file 0001600620-24-000041.txt   1437708

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20231231.xsd EX-101.SCH 1932
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20231231_lab.xml EX-101.LAB 33577
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20231231_pre.xml EX-101.PRE 19550
21 EXTRACTED XBRL INSTANCE DOCUMENT auph-20231231_htm.xml XML 4943
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 981231763 | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36421 | Film No.: 24890939
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)